University of Pennsylvania: Leukemia trials
The registry lists 15 Leukemia studies with University of Pennsylvania as lead sponsor. 0 are open to participants now and 4 have results posted.
Early Phase 1 2Phase 1 11Phase 2 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALLCompletedNCT03792633Phase 2Results posted
- CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALLTerminatedNCT02935543Phase 2Results posted
- Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and LymphomaCompletedNCT01626495Phase 1/2Results posted
- CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to ChemotherapyCompletedNCT01029366Phase 1Results posted
- CART123 + Ruxolitinib in Relapsed/Refractory AMLActive, not recruitingNCT06768476Phase 1
- Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and LymphomaWithdrawnNCT05037669Phase 1
- CD123 Redirected T Cells for AML in Pediatric SubjectsTerminatedNCT04678336Phase 1
- Lentivirally Redirected CD123 Autologous T Cells in AMLTerminatedNCT03766126Phase 1
- Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release SyndromeCompletedNCT02906371Phase 1
- Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)TerminatedNCT02640209Early Phase 1
- CD123 Redirected Autologous T Cells for AMLTerminatedNCT02623582Early Phase 1
- Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT02588456Phase 1
- Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell TherapyCompletedNCT02374333Phase 1
- CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic LeukemiaCompletedNCT01013441Phase 1
- Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantTerminatedNCT00674427Phase 1